Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Pancreatitis Potentially Associated Drugs as a Risk Factor for Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis — Dimitrios Sigounas (2013) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Pancreatitis Potentially Associated Drugs as a Risk Factor for Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Shared by
John P A Ioannidis
Stanford University
Pancreatitis Potentially Associated Drugs as a Risk Factor for Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Article
2013
en
Authors
+5 more
DS
Dimitrios Sigounas
DC
Dimitrios Christodoulou
AT
Athina Tatsioni
Abstract
1 min read
Pancreatitis potentially associated drugs used before ERCP seem to increase the risk for PEP.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Editorial Material
2025
What has changed and remained the same in the past 55 years regarding the prediction and prevention of post<scp>endoscopic retrograde cholangiopancreatography</scp> pancreatitis?
Mamoru Takenaka
,
Masatoshi Kudo
Article
2025
Reconsidering Sedation for Endoscopic Retrograde Cholangiopancreatography: The Potential of Remimazolam
Kosuke Minaga
,
Akane Hara
,
Masatoshi Kudo
Article
2020
High Body Mass Index and Central Adiposity Is Associated with Increased Risk of Acute Pancreatitis: A Meta-Analysis
Dagfinn Aune
,
Yahya Mahamat‐Saleh
,
Teresa Norat
,
Elio Riboli
Article
2006
Spontaneous Perforation of the Bile Duct in a Toddler: The Role of Endoscopic Retrograde Cholangiopancreatography in Diagnosis and Therapy
Peter J Barnes
,
Michael R. Narkewicz
,
Ronald J. Sokol
Article
2001
Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs
Fernie J. A. Penning‐van Beest
,
Erik van Meegen
,
Frits R. Rosendaal
,
Bruno H. Stricker
Clinical Pharmacology & Therapeutics
Discussion(0)
No comments yet. Be the first to comment.